B+
Bull case
25%
Probability
Target price
$70.00
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
TGTX
TG TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q2 commercial execution was strong, guidance was raised, and positive ENHANCE results plus subcutaneous BRIUMVI development extend the product's potential beyond the current regimen. [#SEC-8K-2026-08-03]
Posture
Constructive
Lead driver
Sentiment
What changed
3 setup hits (3d) with net bullish as of 2026-09-09.
What can break
Azer-cel, MG, and schizophrenia programs remain early-stage and may not generate timely validation.
Momentum
80
Value
59
Sentiment
65
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $55.00 · Bull $70.00 · Bear $42.00Analysis 2026-08-06; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-06 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $69.71
Why
Momentum80 · Δ7d +26.2
Value59 · Δ7d -0.0
Sentiment65 · Δ7d +6.8
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-09-09.
- • Sentiment remains the lead driver in the composite, 7D delta +6.8.
Contradictions & invalidation
- • Azer-cel, MG, and schizophrenia programs remain early-stage and may not generate timely validation.
- • High dependence on BRIUMVI commercial momentum and the ability to sustain prescriptions, payer coverage, and supply.
- • The investment case remains concentrated in BRIUMVI, while future value depends on sustained uptake, payer and supply execution, clinical development, and regulatory success.
Catalyst clock
2026-08-03
Q2 commercial strength and raised BRIUMVI guidance
Lead driver: Sentiment · See AI snapshot
Momentum
80
9% active weight
Current posture
7d trendImproving
Δ7d
+26.2
Δ21d
+33.6
Value
59
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+7.6
Sentiment
65
62% active weight
Current posture
7d trendImproving
Δ7d
+6.8
Δ21d
-11.9
Why this grade
Composite grade B. Momentum 80.3 / Value 59.2 / Sentiment 65.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-06. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$55.00
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$42.00
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$7.54B
Beta
1.85
Shares Out
153.07M
P/E (TTM)
10.8
P/S (TTM)
8.92
P/FCF (TTM) · Derived
431.15
Rev YoY
+70.3%
EPS YoY
-71.5%
Gross Margin
+82.4%
Op Margin
+17.1%
Net Debt
$111.74M
Current Ratio
4.27
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data